IAG
AXSM icon

Investmark Advisory Group’s Axsome Therapeutics AXSM Stock Holding History

Investmark Advisory Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100
Closed -$3K – 108
2021
Q4 		$3K Buy
+100
New +$3.68K ﹤0.01% 335

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Investmark Advisory Group's AXSM Position: Q1 2022 in Review

Investmark Advisory Group sold out of Axsome Therapeutics (AXSM) in Q1 2022, closing a stake of 100 shares — an estimated $3K sold.

Investmark Advisory Group first reported a position in AXSM in Q4 2021 and held it in 1 quarter. The position peaked at $3K in Q4 2021. 175 funds tracked by Wall St. Rank hold AXSM as of Q1 2022.

  • Investmark Advisory Group reported no remaining Axsome Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Investmark Advisory Group sold 100 Axsome Therapeutics shares in Q1 2022, an estimated $3K.
  • Investmark Advisory Group first reported a position in Axsome Therapeutics in Q4 2021 and held it in 1 quarter.
  • Investmark Advisory Group's Axsome Therapeutics position peaked at $3K in Q4 2021.
  • 175 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2022.

Based on Investmark Advisory Group's 13F filing for Q1 2022, filed 3 May 2022.